<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134241">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354132</url>
  </required_header>
  <id_info>
    <org_study_id>2008P-000460 BIDMC 42</org_study_id>
    <secondary_id>107865</secondary_id>
    <nct_id>NCT01354132</nct_id>
  </id_info>
  <brief_title>N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis</brief_title>
  <acronym>NACPSY</acronym>
  <official_title>Effects of Oral N-Acetyl-Cysteine (NAC) in the Early Phase of Schizophrenia Spectrum Psychosis: Randomized, Parallel, Double- Blind, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center de Neurosciences Psychiatrique, Lausanne, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators seek to examine the effect of add-on N-Acetyl-Cysteine (NAC) in the early
      phase of schizophrenia spectrum illness in collaboration with researchers Kim Do, PhD, and
      Philippe Conus, MD in Switzerland. Modifications of brain structure are thought to occur
      during the pre-illness phase and around the transition to psychosis. Therefore, studying new
      treatments that could target changes occurring during this period is of critical importance.

      Aims:

      Does add-on NAC treatment in early psychosis influence:

        -  positive and negative symptoms

        -  extrapyramidal side-effects of other medication

        -  plasma concentration of glutathione

        -  Mismatch Negativity, a physiological marker
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study proposes that a glutathione deficit leading to an abnormal response to oxidative
      stress is a vulnerability factor, combined with other brain specific factors, in brain
      functioning of some individuals with schizophrenia (Do et al., 2010). N-acetyl-cysteine is
      hypothesized to cross the blood-brain barrier and increase glutathione in the brain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of negative symptoms on the PANSS</measure>
    <time_frame>within 6 months of NAC treatment</time_frame>
    <description>Positive and Negative Syndrome Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved positive and general symptoms (PANSS) and functional level (GAF &amp; SOFAS)</measure>
    <time_frame>within 6 months of NAC treatment</time_frame>
    <description>Positive and Negative Syndrome Scale Global Assessment of Functioning Social and Occupational Functioning Assessment Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved cognition and working memory (MATRICS)</measure>
    <time_frame>at 24 weeks of NAC treatment</time_frame>
    <description>The MATRICS is neurocognitive battery designed to assess cognition in psychopharmacology studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved EEG/Evoked potentials (Mismatch Negativity)</measure>
    <time_frame>at 24 weeks of NAC treatment</time_frame>
    <description>Mismatch Negativity, a component of auditory evoked potentials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved plasma glutathione</measure>
    <time_frame>within 24 weeks of NAC treatment</time_frame>
    <description>Plasma levels of glutathione, plasma amino acids and genetic analysis of enzymes involved in glutathione metabolism</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Schizophrenic Psychoses</condition>
  <arm_group>
    <arm_group_label>n-acetyl-cysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-Acetyl cysteine effervescent tablets in water 2 in am and 1 in pm for 28 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching effervescent tablets in water 2 in am and 1 in pm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>n-acetylcysteine</intervention_name>
    <description>900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM</description>
    <arm_group_label>n-acetyl-cysteine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PharmaNAC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capacity to provide informed consent

          -  DSM IV TR diagnosis of schizophrenia, schizophreniform, schizoaffective

          -  Psychiatric and medical stability

          -  Prescribing clinician's premission to participate, assurance of medical stability

          -  Having met threshold criteria for psychosis on CAARMS (Comprehensive Assessment of at
             Risk Mental States Scale) Psychosis subscale

          -  Up to 12 months of antipsychotic treatment

        Exclusion Criteria:

          -  Severe medical comorbidities

          -  Previous cerebral trauma

          -  Substance induced psychosis or organic psychosis

          -  Mental retardation

          -  NAC allergy

          -  Pregnancy, females and males planning pregnancy

          -  Treatment with antioxidants

          -  Insufficient command of English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Cousins, PhD, APRN</last_name>
    <role>Study Director</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>T. U. Wilson Woo, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Mental Health Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Do KQ, Conus P, Cuenod M. Redox dysregulation and oxidative stress in schizophrenia: nutrigenetics as a challenge in psychiatric disease prevention. World Rev Nutr Diet. 2010;101:131-53. doi: 10.1159/000314518. Epub 2010 Apr 30. Review.</citation>
    <PMID>20436260</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 26, 2015</lastchanged_date>
  <firstreceived_date>May 13, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Tsung-Ung Wilson Woo</investigator_full_name>
    <investigator_title>Psychiatrist</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>schizoaffective</keyword>
  <keyword>schizophreniform</keyword>
  <keyword>early schizophrenia spectrum psychosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
